LitFin supports women impacted by Essure implants

LitFin has launched a new initiative in France aimed at supporting women who have experienced health complications after receiving the Essure contraceptive implant. The initiative is made possible through collaboration with local partners — the patient Association RESIST - France and the legal team at JVL & Associés.

Essure is a non-surgical permanent birth control method marketed as a less invasive alternative to surgical sterilization. However, over time, many women have reported serious health problems ranging from chronic pain to mood disturbances, abnormal bleeding and inflammatory symptoms.

In September 2018, Bayer reportedly announced that it would permanently discontinue sales of Essure, citing commercial reasons.

Read more.